Beeline Medicines

Beeline Medicines is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing precision therapies for autoimmune and inflammatory diseases. Founded in 2025, the company originated from a Bain Capital-backed spinout of Bristol Myers Squibb, securing $300 million in Series A financing. The company aims to create innovative treatments that address the root causes of immune dysfunction. Its pipeline includes five programs, with key assets such as Afimetoran, a s